Developing it after 80 might help prevent mental decline, research suggests
Nonpartisan report analyzes probable effects of a 2015 Congressional bill
Almost half did not get objective breathing test, researchers in Canada found
U.S. Abortion Rate Drops to Lowest in Decades
Mold Found in Baby Teething Toy
By Toni Clarke and Susan Cornwell WASHINGTON (Reuters) - President-elect Donald Trump's nominee for health secretary was expected to face hard questions from a U.S. Senate panel on Wednesday about his personal stock investments and proposals to dismantle Obamacare. Representative Tom Price, a Georgia orthopedic surgeon who has been in politics for more than 20 years, was chosen by fellow Republican Trump, who will become president on Friday, to head an agency that manages scores of healthcare programs. The Department of Health and Human Services runs the Medicare program for the elderly, Medicaid for the poor and President Barack Obama's Affordable Care Act, which was enacted in 2010 and brought health insurance coverage to millions of Americans who previously lacked it.
Sudan's annual inflation rate rose to 30.47 percent in December from 29.49 percent in November, the Central Statistics Office said on Wednesday, as food and energy prices kept rising after subsidies were cut in early November. Sudan's economic problems have been building since the south seceded in 2011, taking with it three-quarters of the country's oil output, its main source of foreign currency and government income. A dollar shortage and a ballooning black market for hard currency have made imports more expensive.
By Ben Hirschler DAVOS, Switzerland (Reuters) - Donald Trump's plans to cut U.S. corporate tax rates could trigger increased investment in the United States by Novartis, its chief executive told Reuters, despite the president-elect's recent harsh words on drug prices. "When we build a new manufacturing site we think about the tax rate, we think about the economy of the country, we think about jobs, so a booming U.S. economy would make the U.S. more attractive for investment," Joe Jimenez said on Wednesday.
Clinical trials which conclude that the drug being tested works are more likely to be conducted by researchers with financial ties to the pharmaceutical industry, a study said Wednesday. The investigation, published in The BMJ medical journal, was fuelled by concerns about bias on the part of doctors and scientists running drug trials. Nearly 60 percent of some 400 principal investigators in 195 clinical drug trials analysed had traceable financial ties to the drug industry, the researchers found.